Malaysiakini
ENBM中文TA
Sign In
Subscribe
  • LifetimeACTIVEINACTIVEEXPIRED
  • Registered on:Renews on:Expires on:
    ACTIVEINACTIVEEXPIRED
  • Subscribe
  • Renew
  • Extend Subscription
  • Settings
  • Contact Support
  • Sign Out
  • Latest
  • Videos
  • Opinions
  • Yoursay
  • Featured
  • Kini News Lab
  • KiniGuide
  • Sustainability
  • Events
  • Collab Content
  • TopTech
  • Our Team
  • Privacy Policy
  • Terms of Service
  • Advertise with us
  • Careers
  • Email
  • WhatsApp
  • File a complaint
  • Address
Malaysiakini
user
Sign In
Subscribe
ENBM中文TA
  • Latest
  • Videos
  • Opinions
  • Yoursay
  • Featured
  • Kini News Lab
  • KiniGuide
  • Sustainability
  • Events
  • Collab Content
  • TopTech
  • Our Team
  • Privacy Policy
  • Terms of Service
  • Advertise with us
  • Careers
  • Email
  • WhatsApp
  • File a complaint
  • Address
ENBM中文TA

      ANNOUNCEMENT

      He was the sole candidate proposed for the post during a state committee meeting.

      He was the sole candidate proposed for the post during a state committee meeting.

      WHO aims to buy antiviral Covid-19 pills for US$10 - document
      Malaysiakini
      World
      WHO aims to buy antiviral Covid-19 pills for US$10 - document

      WHO aims to buy antiviral Covid-19 pills for US$10 - document

      ReutersPublished: Oct 20, 2021 1:43 AM

      A World Health Organization-led programme to ensure poorer countries get fair access to Covid-19 vaccines, tests and treatments aims to secure antiviral drugs for patients with mild symptoms for as little as US$10 per course, a draft document seen by Reuters says.

      Merck & Co's experimental pill molnupiravir is likely to be one of the drugs, and other drugs to treat mild patients are being developed.

      Merck Covid-19 pill sparks calls for access for lower income countries

      Merck Covid-19 pill sparks calls for access for lower income countries

      Zahid wants govt to explain procurement of molnupiravir

      Zahid wants govt to explain procurement of molnupiravir

      Merck drug less effective against moderate Covid - India regulatory source

      Merck drug less effective against moderate Covid - India regulatory source

      Molnupiravir - the Covid-19 pill

      Molnupiravir - the Covid-19 pill

      MOH ordered experimental antiviral drug due to breakthrough infections - KJ

      MOH ordered experimental antiviral drug due to breakthrough infections - KJ

      Malaysia buys 150,000 courses of Merck's Covid-19 pill

      Malaysia buys 150,000 courses of Merck's Covid-19 pill

      A Covid-19 pill that cuts hospitalisation by 50pct for patients at risk

      A Covid-19 pill that cuts hospitalisation by 50pct for patients at risk

      Merck says research shows its Covid-19 pill works against variants

      Merck says research shows its Covid-19 pill works against variants

      • comments0
      • facebook
      • whatsapp
      • x
      • comments0
      • facebook
      • whatsapp
      • x
      Related reports8

      Merck Covid-19 pill sparks calls for access for lower income countries

      17-10-2021

      Zahid wants govt to explain procurement of molnupiravir

      09-10-2021

      Merck drug less effective against moderate Covid - India regulatory source

      08-10-2021

      Molnupiravir - the Covid-19 pill

      07-10-2021

      MOH ordered experimental antiviral drug due to breakthrough infections - KJ

      07-10-2021

      Malaysia buys 150,000 courses of Merck's Covid-19 pill

      07-10-2021

      A Covid-19 pill that cuts hospitalisation by 50pct for patients at risk

      02-10-2021

      Merck says research shows its Covid-19 pill works against variants

      30-09-2021
      View Comments0

      Comments0

      By posting a comment, you agree to our Commenting Terms and Conditions as stipulated in full here.

      Do's and don'ts when posting comments in Malaysiakini

      TERMS & CONDITIONS

      Foul language, profanity, vulgarity, slanderous, personal attack, threatening, sexually-orientated comments or the use of any method of communication that may violate any law or create needless unpleasantness will not be tolerated. Antisocial behaviour such as "spamming" and "trolling" will be suspended. Violators run the risk of also being blocked permanently.

      REPORT VIOLATORS

      Please use the report feature that is available below each comment to flag offending comments for our moderators to take action. Do not take matters in your own hands to avoid unpleasant and unnecessary exchanges that may result in your own suspension or ban.

      NOTICE

      Our commenting system is still under development. We have taken note of feedback provided.

      Subscriber-only space:

      Are you a subscriber?

      Sign In

      Not yet a subscriber?

      Subscribe

      3200 characters remaining

      Pending comments0

      Are you sure you want to delete this comment?

      This action cannot be undone.

      Report this comment

      500 characters remaining
      mk-logo
      • whatsapp
      • telegram
      • youtube
      • facebook
      • x
      • instagram
      • tiktok
      • linkedin
      • About Us
      • Our Team
      • Privacy Policy
      • Terms of Service
      • Advertise with Us
      • Careers
      • Archive
      • Digital Network
      • KiniTV
      • FG Media
      • RSS Feeds
      • News
      • Opinion
      • Letters
      Contact Editorial
      envelopeeditor@malaysiakini.com
      Contact Subscription/Tech Support
      telephone+6017-323 0707
      envelopesubscribe@malaysiakini.com
      • Advertising
      • advertise@malaysiakini.com
      • advertise@fgmedia.my
      Mkini Dotcom Sdn Bhd
      (199901014818 / 489718-U)No. 9, Jalan 51/205A, Off Jalan Tandang, 46050 Petaling Jaya, Selangor
      Contact Editorial
      envelopeeditor@malaysiakini.com
      Contact Subscription/Tech Support
      telephone+603-7770 0017
      envelopesubscribe@malaysiakini.com
      @Kini
      No. 9, Jalan 51/205A, Off Jalan Tandang, 46050 Petaling Jaya, Selangor